<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Urology reports (St. - Petersburg)</journal-id><journal-title-group><journal-title xml:lang="en">Urology reports (St. - Petersburg)</journal-title><trans-title-group xml:lang="ru"><trans-title>Урологические ведомости</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Urology reports (St. - Petersburg)</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2225-9074</issn><issn publication-format="electronic">2687-1416</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83815</article-id><article-id pub-id-type="doi">10.17816/uroved83815</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Predictive value of inflammatory indices LMR, PLR and NLR in patients with muscle-invasive bladder cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Прогностическое значение воспалительных индексов LMR, PLR и NLR у пациентов с мышечно-инвазивным раком мочевого пузыря</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2858-5317</contrib-id><contrib-id contrib-id-type="scopus">7005253173</contrib-id><contrib-id contrib-id-type="spin">5070-9526</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorelov</surname><given-names>Andrei I.</given-names></name><name xml:lang="ru"><surname>Горелов</surname><given-names>Андрей Игоревич</given-names></name><name xml:lang="zh"><surname>Gorelov</surname><given-names>Andrei I.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor of the Department of Hospital Surgery with a Course of Urology, Head of Urological Unit</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры госпитальной хирургии c курсом урологии, заведующий отделением урологии</p></bio><bio xml:lang="zh"><p>Dr. Sci. (Med.), Professor of the Department of Hospital Surgery with a Course of Urology, Head of Urological Unit</p></bio><email>gorelov_a_i@mail.ru</email><uri>https://med.spbu.ru/prepodavateli/913-gorelov-andrej-igorevich.html</uri><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2556-3390</contrib-id><contrib-id contrib-id-type="spin">3748-7129</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhuravskii</surname><given-names>Dmitriy A.</given-names></name><name xml:lang="ru"><surname>Журавский</surname><given-names>Дмитрий Александрович</given-names></name><name xml:lang="zh"><surname>Zhuravskii</surname><given-names>Dmitriy A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate student</p></bio><bio xml:lang="ru"><p>аспирант</p></bio><bio xml:lang="zh"><p>Postgraduate student</p></bio><email>zhuravskiy.spbu@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7010-7562</contrib-id><contrib-id contrib-id-type="scopus">57202812074</contrib-id><contrib-id contrib-id-type="spin">8568-9004</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorelova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Горелова</surname><given-names>Анна Андреевна</given-names></name><name xml:lang="zh"><surname>Gorelova</surname><given-names>Anna A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Assistant Professor of the Department of Hospital Surgery with a Course of Urology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ассистент кафедры госпитальной хирургии с курсом урологии, ст. н. с.</p></bio><bio xml:lang="zh"><p>Cand. Sci. (Med.), Assistant Professor of the Department of Hospital Surgery with a Course of Urology</p></bio><email>gorelovauro@gmail.com</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff><aff><institution xml:lang="zh">Saint Petersburg State University</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">City Pokrovskaya Hospital</institution></aff><aff><institution xml:lang="ru">Городская Покровская больница</institution></aff><aff><institution xml:lang="zh">City Pokrovskaya Hospital</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Saint-Petersburg University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff><aff><institution xml:lang="zh">Saint-Petersburg University</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">St. Petersburg Research Institute of Phthisiopulmonology</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии</institution></aff><aff><institution xml:lang="zh">St. Petersburg Research Institute of Phthisiopulmonology</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2021-11-23" publication-format="electronic"><day>23</day><month>11</month><year>2021</year></pub-date><pub-date date-type="pub" iso-8601-date="2021-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2021</year></pub-date><volume>11</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>285</fpage><lpage>294</lpage><history><date date-type="received" iso-8601-date="2021-10-26"><day>26</day><month>10</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-23"><day>23</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Gorelov A.I., Zhuravskii D.A., Gorelova A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Горелов А.И., Журавский Д.А., Горелова А.А</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2021, Gorelov A.I., Zhuravskii D.A., Gorelova A.A.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Gorelov A.I., Zhuravskii D.A., Gorelova A.A.</copyright-holder><copyright-holder xml:lang="ru">Горелов А.И., Журавский Д.А., Горелова А.А</copyright-holder><copyright-holder xml:lang="zh">Gorelov A.I., Zhuravskii D.A., Gorelova A.A.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2024-12-15"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/uroved/article/view/83815">https://journals.eco-vector.com/uroved/article/view/83815</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold>: Increasing the efficiency of predicting the results of treatment of patients with bladder cancer is one of the important tasks of modern urology.</p> <p><bold>AIM</bold>: Our aim was to identify and evaluate the association between the most significant clinical, morphological and immunological markers and survival of muscle-invasive bladder cancer patients treated with radical cystectomy. We also developed an algorithm for diagnosis and treatment of patients with muscle-invasive bladder cancer.</p> <p><bold>MATERIALS AND METHODS</bold>: This retrospective study included 100 muscle-invasive bladder cancer patients, who underwent radical cystectomy between 1995 and 2013. The study endpoints were overall survival.</p> <p><bold>RESULTS</bold>: Univariable analysis revealed that continuous (Lymphocyte-monocyte ratio), PLR (platelet-lymphocyte ratio) и NLR (neutrophil-lymphocyte ratio) were significantly associated with overall survival. On multivariable regression model analysis, continuous LMR, NLR, and PLR independently predicted both endpoints.</p> <p><bold>CONCLUSIONS</bold>: Our findings indicate that the cheap and simple blood-based biomarkers may be valuable in identifying muscle-invasive bladder cancer patients treated with radical cystectomy, who are at higher risk of all-cause mortality.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность</bold>. Повышение эффективности прогнозирования результатов лечения больных раком мочевого пузыря — одна из важных задач современной урологии.</p> <p><bold>Цель</bold>. Оценить прогностическую ценность периоперационных иммунологических маркеров LMR (lymphocyte-monocyte ratio — лимфоцитарно-моноцитарный индекс), PLR (platelet-lymphocyte ratio — тромбоцито-лимфоцитарный индекс) и NLR (neutrophil-lymphocyte ratio — нейтрофильно-лимфоцитарный индекс) у пациентов с мышечно-инвазивным раком мочевого пузыря, которым была выполнена радикальная цистэктомия.</p> <p><bold>Материалы и методы</bold>. В ретроспективное исследование были включены 100 пациентов с мышечно-инвазивным раком мочевого пузыря, перенесших радикальную цистэктомию в период с 1995 по 2013 г. Конечной точкой исследования была общая выживаемость.</p> <p><bold>Результаты</bold>. Пятилетняя общая выживаемость была достоверно ниже (р &lt; 0,0001) в группах высокого риска при всех воспалительных индексах и составила 52, 57 и 45 % для PLR-, NLR- и LMR-высоких рисков соответственно. Проведение множественного регрессионного анализа показало, что анализируемые иммунологические маркеры могут использоваться для прогнозирования исходов хирургического лечения.</p> <p><bold>Выводы</bold>. Наши результаты показывают, что дешевый и простой анализ маркеров воспаления могут быть ценными для выявления пациентов высокого и низкого риска с мышечно-инвазивным раком мочевого пузыря, предсказывая эффективность хирургического лечения.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>bladder cancer</kwd><kwd>inflammatory markers</kwd><kwd>radical cystectomy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак мочевого пузыря</kwd><kwd>воспалительные маркеры</kwd><kwd>радикальная цистэктомия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Antoni S, Ferlay J, Soerjomataram I, et al. bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. DOI: 10.1016/j.eururo.2016.06.010</mixed-citation><mixed-citation xml:lang="ru">Antoni S., Ferlay J., Soerjomataram I., et al. Bladder cancer incidence and mortality: a global overview and recent trends // Eur Urol 2017. Vol. 71, No. 1. P. 96–108. DOI: 10.1016/j.eururo.2016.06.010</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin AD, Starinskiy VV, Shahzadova AO, editors. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2019 godu. Moscow: MNIOI Gercena PA; 2020. 239 p.</mixed-citation><mixed-citation xml:lang="ru">Состояние онкологической помощи населению России в 2019 году / под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. Москва: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Ploeg M, Aben KKH, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3): 289–293. DOI: 10.1007/s00345-009-0383-3</mixed-citation><mixed-citation xml:lang="ru">Ploeg M., Aben K.K.H., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world // World J Urol. 2009. Vol. 27, No. 3. P. 289–293. DOI: 10.1007/s00345-009-0383-3</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462–475. DOI: 10.1016/j.eururo.2016.06.020</mixed-citation><mixed-citation xml:lang="ru">Alfred Witjes J., Lebret T., Compérat E.M., et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer // Eur Urol. 2017. Vol. 71, No. 3. P. 462–475. DOI: 10.1016/j.eururo.2016.06.020</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Sharma A, Subudhi SK, Blando J, et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019;25(4):1233–1238. DOI: 10.1158/1078-0432.CCR-18-0762</mixed-citation><mixed-citation xml:lang="ru">Sharma A., Subudhi S.K., Blando J., et al. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers // Clin Cancer Res. 2019. Vol. 25, No. 4. P. 1233–1238. DOI: 10.1158/1078-0432.CCR-18-0762</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Oh BS, Jang JW, Kwon JH, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. DOI: 10.1186/1471-2407-13-78</mixed-citation><mixed-citation xml:lang="ru">Oh B.S., Jang J.W., Kwon J.H., et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma // BMC Cancer 2013. Vol. 13. P. 78. DOI: 10.1186/1471-2407-13-78</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Gurol G, Ciftci IH, Terizi HA, et al. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? J Microbiol Biotechnol. 2015;25(4):521–525. DOI: 10.4014/jmb.1408.08060</mixed-citation><mixed-citation xml:lang="ru">Gurol G., Ciftci I.H., Terizi H.A., et al. Are there standardized cutoff values for neutrophil-lymphocyte ratios in bacteremia or sepsis? // J Microbiol Biotechnol 2015. Vol. 25, No. 4. P. 521–525. DOI: 10.4014/jmb.1408.08060</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Chen ZY, Ragha K, Lieu CH, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112(6):1088–1097. DOI: 10.1038/bjc.2015.61</mixed-citation><mixed-citation xml:lang="ru">Chen Z.Y., Raghav K., Lieu C.H., et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer // Br J Cancer 2015. Vol. 112, No. 6. P. 1088–1097. DOI: 10.1038/bjc.2015.61</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Gakis G. The role of inflammation in bladder cancer. Adv Exp Med Biol. 2014;816:183–196. DOI: 10.1007/978-3-0348-0837-8_8</mixed-citation><mixed-citation xml:lang="ru">Gakis G. The role of inflammation in bladder cancer // Adv Exp Med Biol. 2014. Vol. 816. P. 183–196. DOI: 10.1007/978-3-0348-0837-8_8</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. DOI: 10.1038/nature07205</mixed-citation><mixed-citation xml:lang="ru">Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation // Nature. 2008. Vol. 454, No. 7203. P. 436–444. DOI: 10.1038/nature07205</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Balkarli A, Kucuk A, Babur H, Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volume in Behcet’s disease. Eur Rev Med Pharmacol Sci. 2016;20(14):3045–3050.</mixed-citation><mixed-citation xml:lang="ru">Balkarli A., Kucuk A., Babur H., Erbasan F. Neutrophil/lymphocyte ratio and mean platelet volume in Behcet’s disease // Eur Rev Med Pharmacol Sci. 2016. Vol. 20, No. 14. P. 3045–3050.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Wasilewski J, Pyka Ł, Hawranek M, et al. Prognostic value of neutrophil tolymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure. Pol Arch Med Wewn. 2016;126(3):166–173. DOI: 10.20452/pamw.3316</mixed-citation><mixed-citation xml:lang="ru">Wasilewski J., Pyka Ł., Hawranek M., et al. Prognostic value of neutrophil tolymphocyte ratio in predicting long-term mortality in patients with ischemic and nonischemic heart failure // Pol Arch Med Wewn. 2016. Vol. 126, No. 3. P. 166–173. DOI: 10.20452/pamw.3316</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Sui X, Lei L, Chen L, et al. Inflammatory Microenvironment in the Initiation and Progression of Bladder Cancer. Oncotarget. 2017;8(54):93279–93294. DOI: 10.18632/oncotarget.21565</mixed-citation><mixed-citation xml:lang="ru">Sui X., Lei L., Chen L., et al. Inflammatory Microenvironment in the Initiation and Progression of Bladder Cancer // Oncotarget. 2017. Vol. 8, No. 54. P. 93279–93294. DOI: 10.18632/oncotarget.21565</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Kim J, Bae JS. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016;2016:6058147. DOI: 10.1155/2016/6058147</mixed-citation><mixed-citation xml:lang="ru">Kim J., Bae J.S. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment // Mediators Inflamm. 2016. Vol. 2016. P. 6058147. DOI: 10.1155/2016/6058147</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2): 137–148. DOI: 10.1016/j.immuni.2004.07.017</mixed-citation><mixed-citation xml:lang="ru">Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting // Immunity. 2004. Vol. 21, No. 2. P. 137–148. DOI: 10.1016/j.immuni.2004.07.017</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104(10):3967–3972. DOI: 10.1073/pnas.0611618104</mixed-citation><mixed-citation xml:lang="ru">Sharma P., Shen Y., Wen S., et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma // Proc Natl Acad Sci USA. 2007. Vol. 104, No. 10. P. 3967–3972. DOI: 10.1073/pnas.0611618104</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Morizawa Y, Miyake M, Shimada K, at al. Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer. Cancer Invest. 2018;36(7):395–405. DOI: 10.1080/07357907.2018.1506800</mixed-citation><mixed-citation xml:lang="ru">Morizawa Y., Miyake M., Shimada K., at al. Correlation of Immune Cells and Cytokines in the Tumor Microenvironment with Elevated Neutrophil-To-Lymphocyte Ratio in Blood: An Analysis of Muscle-Invasive Bladder Cancer // Cancer Invest. 2018. Vol. 36, No. 7. P. 395–405. DOI: 10.1080/07357907.2018.1506800</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Miyake M, Hori S, Morizawa Y, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia. 2016;18(10):636–646. DOI: 10.1016/j.neo.2016.08.002</mixed-citation><mixed-citation xml:lang="ru">Miyake M., Hori S., Morizawa Y., et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer // Neoplasia. 2016. Vol. 18, No. 10. P. 636–646. DOI: 10.1016/j.neo.2016.08.002</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Khaki AR, Agarwal N, Pal SK, Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer. 2020;126(20):4446–4450. DOI: 10.1002/cncr.33068</mixed-citation><mixed-citation xml:lang="ru">Khaki A.R., Agarwal N., Pal S.K., Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest // Cancer. 2020. Vol. 126, No. 20. P. 4446–4450. DOI: 10.1002/cncr.33068</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Kaiser J, Li H, North SA, et al. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. Bladder Cancer. 2018;4(2):185–194. DOI: 10.3233/BLC-170133</mixed-citation><mixed-citation xml:lang="ru">Kaiser J., Li H., North S.A., et al. The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study // Bladder Cancer. 2018. Vol. 4, No. 2. P. 185–194. DOI: 10.3233/BLC-170133</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Rajwa P, Życzkowski M, Paradysz A, et al. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur Rev Med Pharmacol Sci. 2018;22(10):3027–3037. DOI: 10.26355/eurrev_201805_15060</mixed-citation><mixed-citation xml:lang="ru">Rajwa P., Życzkowski M., Paradysz A., et al. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy // Eur Rev Med Pharmacol Sci. 2018. Vol. 22, No. 10. P. 3027–3037. DOI: 10.26355/eurrev_201805_15060</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Tamura S, Wang Y, Veeneman B, et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer. Bladder Cancer. 2018;4(1):77–90. DOI: 10.3233/BLC-170144</mixed-citation><mixed-citation xml:lang="ru">Tamura S., Wang Y., Veeneman B., et al. Molecular correlates of in vitro responses to dacomitinib and afatinib in bladder cancer // Bladder Cancer. 2018. Vol. 4, No. 1. P. 77–90. DOI: 10.3233/BLC-170144</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang J, Zhou X, Ding H, et al. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer. BMC Urol. 2020;20(1):31. DOI: 10.1186/s12894-020-00602-9</mixed-citation><mixed-citation xml:lang="ru">Zhang J., Zhou X., Ding H., et al. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer // BMC Urol. 2020. Vol. 20, No. 1. P. 31. DOI: 10.1186/s12894-020-00602-9</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Ma X, Li H, Chen L, et al. Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram. Sci Rep. 2016;6:23846. DOI: 10.1038/srep23846</mixed-citation><mixed-citation xml:lang="ru">Ma X., Li H., Chen L., et al. Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram // Sci Rep. 2016. Vol. 6. P. 23846. DOI: 10.1038/srep23846</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Neal CP, Cairns V, Jones MJ, et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol. 2015;32(5):144. DOI: 10.1007/s12032-015-0590-2</mixed-citation><mixed-citation xml:lang="ru">Neal C.P., Cairns V., Jones M.J., et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases // Med Oncol. 2015. Vol. 32, No. 5. P. 144. DOI: 10.1007/s12032-015-0590-2</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">D’Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017;115(4):455–461. DOI: 10.1002/jso.24521</mixed-citation><mixed-citation xml:lang="ru">D’Andrea D., Moschini M., Gust K.M., et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy // J Surg Oncol. 2017. Vol. 115, No. 4. P. 455–461. DOI: 10.1002/jso.24521</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang GM, Zhu Y, Luo L, et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol. 2015;36(11):8537–8543. DOI: 10.1007/s13277-015-3613-x</mixed-citation><mixed-citation xml:lang="ru">Zhang G.M., Zhu Y., Luo L., et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy // Tumour Biol. 2015. Vol. 36, No. 11. P. 8537–8543. DOI: 10.1007/s13277-015-3613-x</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Bhindi B, Hermanns T, Wei Y, et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J Cancer. 2016;114(2):207–212. DOI: 10.1038/bjc.2015.432</mixed-citation><mixed-citation xml:lang="ru">Bhindi B., Hermanns T., Wei Y., et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy // Br J Cancer. 2016. Vol. 114, No. 2. P. 207–212. DOI: 10.1038/bjc.2015.432</mixed-citation></citation-alternatives></ref></ref-list></back></article>
